About azacitidine after
Pyrimidine nucleoside analogue; antineoplastic
Used for
- Treats myelodysplastic syndromes, including higher-risk disease.
- Treats acute myeloid leukemia in selected adults not suited to stem-cell transplant.
Usual adult dose
Commonly 75 mg/m² under the skin or into a vein daily for 7 days, repeated every 28 days; specialist-directed adjustments apply.
Common side effects
- Low blood-cell counts, increasing infection or bleeding risk
- Nausea, vomiting, diarrhea, or constipation
- Injection-site reactions
- Fever, fatigue, or weakness
Important warnings
- Requires specialist supervision and regular blood-count monitoring.
- Can cause severe bone-marrow suppression, infections, or bleeding.
- May harm an unborn baby; pregnancy testing and effective contraception are important.
- Use caution with kidney or liver problems.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is recommended during treatment and for six months afterward for women.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Other medicines that suppress bone marrow may increase low blood counts.
- Medicines affecting kidney function may increase toxicity risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.